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Introduction
Burning Mouth Syndrome (BMS) is distinguished by burning, 
pain, or symptoms of itching in oral mucosa, which arise 
without the presence of any changes in physical examinations, 
laboratory analysis, or salivary flow rates [1-5]. This condition 
tends to appear in middle-aged and elderly women [6-9]. The 
International Association for the Study of Pain defines BMS 
as a pain that lasts for at least 4-6 months of duration and 
which is located on tongue or in other mucosal membranes 
and that is presented in the absence of any clinical and/or 
laboratory findings. The terms “glossodynia” (painful tongue) 
and “glossopyrosis” (burning tongue), as well as “glossalgia”, 
describe the phenomenon present in this disorder with 
respect to the most affected area, the tongue (especially the 
tip and lateral borders). Other terms such as “stomatodynia”, 
“stomatopyrosis”, “oral dysesthesia”, and “burning mouth 
syndrome” are used to define this condition [10]. Although 
percentages in research findings may vary between .07% and 
15%, we can state that this disease is highly prevalent [11].
The episodes of a burning sensation are described as being 
spontaneous and the symptoms that patients experience range 
in severity; some patients suffer from a moderate burn, while 
others experience intolerable pain [3,12]. Other changes in 
sensitivity are known to take place, besides oral stinging, which 
include: a feeling of dryness in the mouth [13-15] or gustative 
alterations, such as the perception of a bitter or metallic taste 
[16]. In certain instances dysesthesia in the mouth might also 
occur, which is characterized by the feeling of having sand in 
the mouth or swelling of the mouth [12,16,17]. 
The lack of unified criteria makes the diagnosis even more 
complicated, and consequently, epidemiological information 
can differ depending on the researcher who analyzes it 
[18,19]. Within the risk group of postmenopausal-women, 
the prevalence of this disorder ranges between 18% and 33% 
[20]. The majority of research conducted shows an evident 
predominance that women have over men, ranging between 
3-1 and 9-1 for the female sex [21-24]. According to most of 
the authors, the typical average age of patients of BMS is from 
50 to 60 years old, however, it can also arise in patients close 
to their thirties, but not in children or in teenagers. 
The true cause BMS remains unknown. Although this 
syndrome is not accompanied by evident organic alterations 
and it does not present health risks, it can significantly 
reduce the patient’s quality of life. BMS patients tend to 
have a history of frequent medical and dental visits with the 
objective of obtaining a cure that does not yet exist. Experts 
currently debate whether the psychological alterations that 
BMS patients experience are the cause or the consequence of 
such chronic pain [25-27]. The patient profile is rather specific 
and is comprised of the following personal characteristics: 
age range between 50 and 60, a history of prolonged suffering 
from chronic pain, and a history of having been treated by 
many different specialists without obtaining any solution to 
the problem. It is also often accompanied by a significant 
emotional profile and is usually related to cancerophobia [28]. 
Diligent clinical investigation fails to accurately identify 
the cause for the burning sensation in patients with true burning 
mouth syndrome.  Specific criteria should be observed, since 
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symptoms of oral burning are common and can be caused 
by either local or systemic factors, which do not describe 
true BMS [15-17,28]. The clinical or laboratorial conditions 
associated with burning mouth include candidiasis, geographic 
tongue, hyposalivation, esophagic reflux, parafunctional 
habits, diabetes, nutritional deficiencies (iron, folate, B
1
, B
2
, 
B
6
, B
12
), and adverse effects of certain drugs. In such cases, 
if the cause of this disorder is eliminated, the patient will 
therefore experience symptom relief [29].
This study analyzes the available literature related to BMS, 
and makes special reference to its therapeutic management. 
Other important topics of discussion throughout this article 
also include the diagnostic criteria that should be followed, 
etiological factors, and clinical aspects of the disease.
A search in the PubMed database was performed in order 
to identify articles published in the last five years using the 
key words: "burning mouth syndrome", "BMS and review", 
and "burning mouth and review". This search resulted in 259 
articles. When we limited the search to articles published in 
the English language, we found 6 non-systematic reviews 
and one systematic review that we considered particularly 
relevant (Table 1)".
The objective of this article was to perform a literature 
review on BMS based on three main sections: pathogenesis, 
diagnosis, and treatment, with a special focus on the latter.
Pathogenesis
The origin of BMS includes a variety of factors. We can 
divide the possible causes of BMS into local factors [26,30-
36], systemic factors [26,37] and psychological factors such 
as: stress, anxiety and depression [2,12,30,31,37,38]. At times 
BMS can be directly related to a pathogenic factor that can act 
in either a local or systemic way. However, there are certain 
cases of idiopathic stomatodynia in which none of them are 
shown [39].
According to some authors, BMS is included within the 
group of diseases categorized by idiopathic orofacial pain 
[40]. Such disease share the common features that in all cases 
the pain is continuous, it is chronic for several months, and 
then it disappears while the patient is sleeping. It is known 
to be more common in women and it is closely related to 
psychosocial disorders [11,30]. 
Local allergic reactions may also have a possible influence 
on the etiology of BMS.  Possible allergens include: allergens 
from dental materials or materials used in the manufacturing 
of prosthesis, especially in type III patients [41]. However, 
throughout the BMS literature there are some authors who do 
not pay special attention to such factors [42]. There are other 
agents and/or elements that must also be taken into account, 
these include: cosmetics, toothpastes and mouthwashes, all 
of which could provoke the sensation of oral burning and 
stinging [39].
Article Aspects from the review Most relevant conclusions
Abetz and Savage [32]
No systematic review. 
This publication serves as a review of BMS’ 
clinical presentation and focuses on contributing 
factors in the initial presentation of the 
condition, as well as its advancement.
A number of useful clinical indicators were proposed in this 
paper, these indicators or signs may prove to be helpful for 
both clinical assessment and subsequent patient discussions, 
seeing as they provide visible supportive evidence for the 
diagnosis. The main focal point of the article was the role of 
psychological disorders in the etiology of BMS, in addition 
to a presentation that highlighted the clinical management of 
patients.
Balasubramaniam et al. [16]
No systematic review.
The article reviews different conditions and 
diseases that may be possible causes of oral 
burning.
The article provided knowledge about the local, systemic and 
psychosocial factors that can cause the onset of oral burning, 
which is associated with secondary BMS.
López-Jornet et al. [9]
No systematic review.
The article reviews some recent studies related 
to BMS literature, especially those having 
to do with etiological factors that could be 
involved, clinical aspects, diagnostic criteria and 
therapeutic management.
The article included tables that helped to guide us through 
the clinical factors, diagnosis and treatment of burning 
mouth syndrome. It made the suggestion of the inclusion and 
exclusion protocols based on suggestions made throughout 
other literary sources.
Minguez-Sanz et al. [29]
No systematic review.
The article describes different hypotheses 
relating to BMS etiology, as well as the 
psychological and anatomical data that serve as 
the basis for such hypotheses.
The study went in depth to describe the different theories that 
have been proposed as an explanation for the primary and 
idiopathic BMS etiology.
De Moraes et al. [34]
Systematic review.
This study reviews several randomized clinical 
trials related to BMS treatment strategies.
The paper provided evidence in favor of the effectiveness 
of therapies and their main side effects with the objective of 
contributing to better therapeutic management of BMS.
Jääskeläinen [28]
No systematic review.
This review recaps the recent neurophysiologic, 
psychophysical, neuropathological, and brain 
imaging evidence for neuropathic mechanisms 
in primary BMS.
The study set forth a thorough neurophysiological, 
psychophysical and neuropathological BMS approach.
Spanemberg et al. [35]
No systematic review.
Different options for the management of BMS 
patients are proposed.  These include etiological 
and therapeutical ones.
The article focused on BMS etiological and treatment options. 
In addition to this, it included a table summarizing the BMS 
placebo treatment.
Table 1. Most significant conclusions from the articles.
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Some authors consider xerostomia to be one of the most 
important coexisting causes and they directly relate it to the 
onset of BMS [43,44].
Systemic factors such as vitamin deficiencies, that can 
produce significant alterations on the tongue, may also play 
an important role in the development of burning mouth. 
Different types of glossitis can appear depending on the 
deficiencies of riboflavin, nicotinic acid, and ascorbic acid, 
and as a result of the alteration in sensitive receptors and, 
in some degree, to the atrophy of the oral epithelium. Due 
to all of these factors, the mucosal sensitivity to external 
agents is increased [45,46]. Diabetes mellitus is frequently 
accompanied by stomatodynia, which can be produced by two 
mechanisms: peripheral neuropathy of the sensory nerves of 
oral mucosa and/or by the degree of xerostomia associated 
with fungal infection [47].
Although no study has yet demonstrated their direct 
relationship with burning mouth syndrome [48], it is true 
that psychological factors play an important role in the 
onset of BMS [48]. According to some authors, stress is not 
considered to be a crucial factor in the appearance of BMS 
symptomatology [48], however the majority of these authors 
do agree that there is a significant relationship between 
the existence of psychogenic alterations (such as: anxiety, 
cancerphobia, and depression) and the manifestation of BMS. 
Femiano et al. [2] have shown that patients who suffer from 
BMS exhibit a decrease in self-esteem, the absence of a solid 
and satisfactory personality, and they experience significant 
losses and important changes in their lives before being 
affected by the syndrome. Patients with BMS, as mentioned 
by Gao et al. [11], have suffered many unfavorable or negative 
events throughout their lives, when comparing them to the 
control-patients. Palacios-Sánchez [49] believes that there 
is an obvious link between the affective life alteration and 
the syndrome’s onset. Patients who suffer from BMS have 
proved to have significantly higher levels of anxiety in their 
lives, as well as higher salivary cortisol levels than those of 
the control-patients [50].
Disorders of the hormone balance may be related to BMS 
in women as the disease is more frequent during and after 
menopause [23,37,51]. Tarkkila et al. [23] evaluated the 
relation between oral discomfort and menopause in 3173 
patients, verifying that 8% of these women exhibited burning 
sensations of the oral tissues. However, hormone replacement 
therapy did not prevent the occurrence of symptoms. In 
Forabosco et al. [37] symptoms of BMS were found in 46% of 
women at menopause and approximately 60% showed relief 
after hormone replacement. The authors attributed the relief 
of oral discomfort following hormone therapy, to the presence 
of oestrogen receptors on the oral mucosa. 
Clinical Signs and Diagnosis
The clinical manifestation of BMS is described by a continual 
hot, burning and painful sensation that lasts throughout the 
day. It is a chronic disease that appears at different locations 
within the oral cavity, all of course in the absence of any 
type of lesion that could justify the symptoms, as well as 
any clinical or histological changes [39,52]. Patients tend to 
complain of a sensation of dry mouth and palate alterations, 
which include a metallic or bitter taste [24,35].
The tongue is the most common location of BMS 
manifestation (at the tip and at the lateral edges), together 
with lips, especially the lower lip [39]. The description of the 
symptomatology varies depending from patient to patient, 
although the majority of them describe the symptoms as 
unbearable and with prolonged evolution. The feeling of 
discomfort tends to be continuous, or it can be intermittent, 
and it often worsens throughout the day. Some patients, 
however, experience days without any symptoms. 
It is important for us to consider that the burning sensation 
can worsen in the presence of specific foods, such as spicy 
food or acidic fruit, and it can even improve with intake of 
liquids, salivary stimulants or with certain foods. Many 
patients notice an improvement when they consume sweets 
or chewing gum, since their mouth is normally dry and left 
with a bad taste, due to the fact that they are taking xerostomia 
causing drugs (antidepressants, anxiolytics or hypotensive 
drugs, among others). Additionally, very hot or very cold food 
can aggravate or improve the BMS related discomfort [39].
BMS is usually sometimes divided into three different types 
[53]. Both types I and II involve continual daily discomfort. 
For type III patients, those that experience asymptomatic 
periods, the main precipitating factor is emotional instability, 
although the onset of symptoms is also related to the exposure 
to a possible allergenic factor that triggers a contact allergy 
[54,55]. This classification can be useful in intuiting the 
prognosis and, at the same time, it allows us to guide the 
patients towards the need involve different specialists such 
as allergologist, psychiatrists and/or psychologists; although 
patient classification based on those three groups is not always 
an easy task. 
The symptoms affect the patients’ quality of life 
[9,31,52,56,57] and due to the significant emotional 
component that goes along with BMS, it is advisable that 
these patients’ visits be quiet, one-on-one with the physician, 
and held in a relaxed environment so that he/she can explain 
his/her familiar and affective situation. These patients need 
time and dedication from their medical professional, seeing as 
they want to be heard and understood. Patient reassurance is 
paramount [31,57]. BMS patients tend to be characterized by 
a common profile; this profile is later summarized in Table 2.
The sensation of xerostomia or dry mouth is something 
that the majority of BMS patients experience although, in 
most of them, it is not possible to demonstrate a significant 
reduction in salivary flow [39]. More often than not, patients 
report symptoms of thick and filamentous saliva. There are 
few unusual cases in which the oral dryness has made food 
intake difficult. On the other hand, the majority of BMS 
patients report improvements with respect to their overall 
discomfort and the burning sensation during food intake.
BMS diagnosis is fundamentally based on clinical signs. 
It is necessary to correctly examine the patient, discarding the 
existence of systemic and local factors that could cause such 
symptoms [39,52,55,57,58]. The administration of a blood 
test is also highly recommended. In the case that any deficit 
should appear, replacement therapy will be initiated, and if in 
spite of this therapy the symptomatology persists, we at that 
point face idiopathic BMS, and therefore, we must begin with 
symptomatic treatment.
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Treatment
BMS treatment is currently still posing serious problems, 
since the etiopathogenic factors that produce the onset of the 
disease, make it difficult to achieve advances in treatment. 
The main objective of the treatment is to control the various 
factors that are related to BMS, therefore decreasing the 
symptoms that are described by the patients. 
As mentioned in some studies, topical capsaicin 
(Capsicum frutescens L) can be used to control neuropathic 
pain, since this drug has an effect on the sensory afferent 
neurons and also serves as an analgesic [51,59,60]. However, 
the use of capsaicin has been reduced since it has been proven 
to evoke an even worse burning sensation at the beginning 
of the treatment period [59]. It is important to note that there 
have not been any cases in which this BMS treatment drug 
has been investigated in placebo-controlled studies. 
Medicine such as tricyclic antidepressants, 
benzodiazepines, and antipsychotic drugs have been 
researched and are considered to be the three most widely 
accepted options for the treatment of BMS, despite the fact 
that they produce hyposalivation and xerostomia. Treatment 
methods like psychotherapy and psychoactive drugs were 
prescribed for BMS patients once it was demonstrated that 
psychological factors play an important role in this disorder 
[61]. Bergdahl et al. [61] treated BMS patients by means 
of cognitive behavior therapy once a week for between 12 
and 15 weeks. They were able to observe a decrease in the 
intensity of the pain immediately after undergoing the therapy 
and at the six-month follow-up visit.
The use of topical clonazepam proved to be another 
treatment option for patients suffering from BMS [51,62-64]. 
Clonazepam is a benzodiazepine that acts as a GABA receptor 
agonist.  Its main property includes the light inhibition of 
functions of the central nervous system, thus permitting 
anticonvulsant action, light sedation, muscular relaxation and 
a calming effect. Gremeau-Richard et al. [62] propose that the 
action of topical clonazepam has to do with the dysfunctions 
of the peripheral nervous system that are observed in patients 
with the syndrome, and the presence of GABA receptors in 
peripheral tissues. Another study was carried out in which 33 
patients were treated with clonazepam tablets, while the other 
33 patients were administered a placebo. The symptoms were 
then assessed after 1 month and 6 months of the treatment 
period had elapsed. After only 1 month of treatment, 23 of 
the 33 patients that were treated with clonazepam reported 
at least a 50% reduction in their symptoms [63]. This drug 
does not show the adverse effects of its systemic use when it 
is used topically.
In an uncontrolled study paroxetine, a tricyclic 
antidepressant, was administered to BMS patients throughout 
a period of 12 weeks [65]. Of these patients, approximately 
80% reported a decrease in their symptoms, with little 
adverse effects, thus suggesting that paroxetine could be a 
plausible treatment option for this disorder. Ueda [66] used 
the antipsychotic drug olanzapine and were therefore able to 
achieve symptom reduction in two patients that suffered from 
the syndrome. Olanzapine is classified as a potent antagonist 
of dopamine, norepinephrine and serotonin neuron receptors. 
However, in order to confirm the effectiveness of this drug, 
and to explain its mechanisms of action, the realization of 
controlled studies is needed.
A drug that did not show suitable results in the relief of 
the symptoms of oral burning was trazodone, a drug that is 
typically used to treat depression. Trazodone is classified as 
an atypical antidepressant since it stimulates the presynaptic 
inhibition of serotonin recaptation, blockage of 5-HT2A and 
5HT2C serotonin receptors on post-synapse neurons [58].
Hormonal treatments, or those that involve corticosteroids, 
phytotherapy, vitamins and trace elements, antifungal drugs 
and sialogogue drugs have also been described throughout the 
literature as an attempt to reduce the symptoms reported by 
the patients, although the studies are not always controlled 
and the patients’ clinical symptoms do not always improve. 
Because of alpha-lipoic acid’s neuroprotective properties, 
it has been researched with respect to BMS treatment; 
however, studies involving this drug have presented 
controversial results. According to Femiano et al. [2], both 
patients treated with psychotherapy and those who received 
200 mg of ALA three times a day throughout a period of 
two months, demonstrated significant improvement with 
respect to their symptoms of BMS. The group that was 
simultaneously treated with ALA and psychotherapy was the 
group that showed the most remarkable results. According 
to the researchers, it is necessary to combine psychotherapy 
with the drugs, the reason for this being that psychogenic 
alterations are known to have a strong relation to BMS [2]. 
Carbone et al. [67], López-Jornet et al. [68] and Cavalcanti 
and Silveira [29] were not able to demonstrate any significant 
improvement in BMS patients when utilizing alpha-lipoic 
acid. Both the placebo effect and the different parameters that 
were used to calculate the intensity of the symptoms could 
be the source of possible explanations that account for such 
conflicting results.
Most common in middle-aged or elderly women 
Characterized by a burning, stinging and/or itching sensation
Patients usually experience a metallic or bitter taste
Oral discomfort is usually chronic and it lasts over time (months 
or years)
Patients usually experience dry mouth or a sensation of thick saliva 
No clinical lesions related to the area of discomfort
Symptoms don’t interfere with patients’ ability to sleep, although 
most of them have trouble sleeping or take drugs in order to be able 
to sleep better
Oral discomfort can be continuous or intermittent and it tends to 
worsen throughout the day
Symptoms don’t worsen while eating or drinking, they can even 
improve
Patients usually have a history of having visited different 
specialists and having taken numerous drugs without observing any 
improvement
They usually have a significant anxious or depressive factor, 
sometimes accompanied by cancerophobia 
Clinical manifestations are usually triggered by psychological 
stress and they often appear after a dental treatment or a surgical 
intervention
Sometimes there is a clear beginning is marked, but with no clear 
trigger
Thanks to internet and social networking websites, many patients 
can self-diagnose
Table 2. Profile of patients with burning mouth syndrome.
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In a controlled study that consisted of 60 patients, the 
phytotherapeutic drug Catuama®, which is composed of an 
association of four medicinal herbs, proved to be effective 
in reducing BMS symptoms in those who suffer from 
this disorder. The experimental group showed clinical 
improvement in week 4 and week 8 that was significant when 
compared to that of the placebo group. After 12 weeks of 
monitoring, the patients experienced a 51.3% reduction in 
their symptoms, whereas the reduction of symptoms in the 
control group was only about 18.8% [69]. There were no 
cases of toxicity with respect to the use of this medicine. In 
a previous study, Oliveira et al. [70] researched the chronic 
administration of Catuama® 25ml, twice a day for 28 days 
in healthy humans volunteers of both sexes. There were no 
adverse reactions or relevant hematological and biochemical 
changes that were presented in the study.
Low power laser radiation therapy has proven to be useful 
in the reduction of BMS symptoms [71-74]. On the contrary, 
Vukoja et al. [74] were not able to confirm those results and 
therefore suggest that the therapeutic benefit of the laser BMS 
patients was caused by placebo effect. Santos et al. [72] had 
10 BMS patients undergo to a low power laser session (low-
level laser therapy - LLLT) once a week over a 10-week 
span, utilizing the InGaAIP laser diode in continuous mode. 
A 660 nm wavelength, 40 nW, 20 J/cm2 of dosimetry and a 
0.8 J per point in 10 seconds was used. Throughout all of the 
sessions the intensity of the symptoms was evaluated by using 
a visual analog scale. Patients reported an improvement after 
laser treatment, with a reduction of symptoms of up to 58% 
by the tenth session. On the other hand Kato et al. [71] used 
the LLLT in 11 patients with BMS at the specific areas where 
the patients were experiencing symptoms. The affected areas 
were irradiated once a week, in a continuous mode, with a 
790 wavelength and a dosimetry of 6 J/cm2. The intensity 
of the symptoms was verified through a VAS at each of the 
three sessions, as well as six weeks after the treatment was 
finished. At the end of the study the authors checked that the 
experimental group did in fact show a significant improvement 
in their symptoms as compared to their state at the beginning 
of the treatment. The patients reported a decrease in the 
intensity of their symptoms after the laser radiation treatment. 
This decrease was approximately 80.4%, therefore suggesting 
that LLLT can be an alternative for BMS. 
Low power laser therapy is a non-invasive treatment; it 
is well tolerated by patients and it is useful in treating sharp 
and chronic pain [40]. Different studies have investigated the 
possible adverse effects of laser but they were not significant 
[75,76].
BMS treatment is usually directed towards symptoms 
management, but local factors they may play a role in 
worsening the oral burning sensation should be eliminated 
[77].  These include: alcohol, spicy foods and acidic drinks 
due to their irritant effect on the oral mucosa. It is necessary 
to research if BMS symptoms are caused by parafunctional 
habits, galvanic currents, mechanical irritation, or a denture 
allergy [6]. With treatment or ridding of such factors, it has 
been demonstrated that the clinical symptoms improve [37,77-
79].  This disease has a chronic clinical evolution seeing as 
patients experience alternating periods of exacerbation of 
the symptomatology, as well as periods of improvement. In 
some cases, those who suffer from BMS have also described 
spontaneous remission [77].
The typical BMS patient seeks diagnosis before undergoing 
any kind of special treatment. Therefore, the medical 
professional has the obligation of explaining the nature of 
BMS and what that implies for the patient. Unfortunately, 
those who are affected by this disorder must accept that fact 
and learn to cope with it, and in turn, they must be conscious 
of that fact that the solution to this disorder may not be found 
in the short term [27].
Conclusions 
BMS patient management is difficult, and more times than 
not, a frustrating task. However, it is essential to not only 
acknowledge the patient but also reassure him/her. The main 
objective of management is that of providing support to the 
patient and working towards symptom reduction, rather than 
total elimination of such symptoms. The complexity of this 
disease, as well as the ignorance of the mechanisms that cause 
its onset, are two key topics that need to be further researched. 
Such insight could enable us to establish effective treatment for 
this disorder. Finally, it is crucial for us to evaluate the quality 
of life of those BMS patients, trying to fully comprehend the 
impact that this condition has on all aspects of their lives. 
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